CN1165518C - 作为药学试剂的双环氨基酸类化合物 - Google Patents

作为药学试剂的双环氨基酸类化合物 Download PDF

Info

Publication number
CN1165518C
CN1165518C CNB008145644A CN00814564A CN1165518C CN 1165518 C CN1165518 C CN 1165518C CN B008145644 A CNB008145644 A CN B008145644A CN 00814564 A CN00814564 A CN 00814564A CN 1165518 C CN1165518 C CN 1165518C
Authority
CN
China
Prior art keywords
acetate
amino methyl
mixture
compound
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008145644A
Other languages
English (en)
Chinese (zh)
Other versions
CN1382118A (zh
Inventor
Js
J·S·布赖恩斯
��Ī������
D·C·布莱克莫尔
S·奥斯博恩
ά
J－M·里斯维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1382118A publication Critical patent/CN1382118A/zh
Application granted granted Critical
Publication of CN1165518C publication Critical patent/CN1165518C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
CNB008145644A 1999-10-20 2000-10-17 作为药学试剂的双环氨基酸类化合物 Expired - Fee Related CN1165518C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20
US60/160,725 1999-10-20

Publications (2)

Publication Number Publication Date
CN1382118A CN1382118A (zh) 2002-11-27
CN1165518C true CN1165518C (zh) 2004-09-08

Family

ID=22578159

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008145644A Expired - Fee Related CN1165518C (zh) 1999-10-20 2000-10-17 作为药学试剂的双环氨基酸类化合物

Country Status (50)

Country Link
US (2) US6689906B1 (enExample)
EP (2) EP1226110B1 (enExample)
JP (2) JP3632191B2 (enExample)
KR (2) KR100566462B1 (enExample)
CN (1) CN1165518C (enExample)
AP (2) AP2002002517A0 (enExample)
AR (2) AR026087A1 (enExample)
AT (2) ATE293590T1 (enExample)
AU (2) AU778871B2 (enExample)
BG (2) BG108860A (enExample)
BR (1) BR0014972B1 (enExample)
CA (1) CA2386297C (enExample)
CO (1) CO5280060A1 (enExample)
CR (1) CR6620A (enExample)
CU (1) CU23112A3 (enExample)
CZ (1) CZ295960B6 (enExample)
DE (2) DE60019628T2 (enExample)
DO (1) DOP2000000083A (enExample)
DZ (1) DZ3197A1 (enExample)
EA (1) EA005206B1 (enExample)
EC (1) ECSP045393A (enExample)
EE (1) EE200200211A (enExample)
ES (2) ES2282785T3 (enExample)
GE (1) GEP20043297B (enExample)
GT (2) GT200000183AA (enExample)
HK (1) HK1049826B (enExample)
HN (1) HN2000000224A (enExample)
HR (2) HRP20040709A2 (enExample)
HU (1) HUP0203325A3 (enExample)
IL (3) IL149143A0 (enExample)
IS (2) IS6348A (enExample)
MA (1) MA26842A1 (enExample)
MX (1) MXPA02003229A (enExample)
MY (1) MY127678A (enExample)
NO (2) NO20021780L (enExample)
NZ (1) NZ517961A (enExample)
OA (1) OA12070A (enExample)
PA (1) PA8505201A1 (enExample)
PE (1) PE20010740A1 (enExample)
PL (1) PL354607A1 (enExample)
PT (1) PT1226110E (enExample)
SI (1) SI1226110T1 (enExample)
SK (1) SK5232002A3 (enExample)
SV (1) SV2001000188A (enExample)
TR (2) TR200201094T2 (enExample)
TW (2) TWI225855B (enExample)
UA (1) UA72931C2 (enExample)
WO (1) WO2001028978A1 (enExample)
YU (2) YU29302A (enExample)
ZA (1) ZA200202543B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
BR0111913A (pt) * 2000-06-26 2004-01-06 Warner Lambert Co Análogos de gabapentina para distúrbios do sono
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
KR100618743B1 (ko) 2001-04-19 2006-08-31 워너-램버트 캄파니 엘엘씨 융합된 비사이클릭 또는 트리사이클릭 아미노산
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6833140B2 (en) * 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
NZ532624A (en) 2002-01-31 2007-05-31 Warner Lambert Co Alpha2delta ligands to treat tinnitus
WO2003070237A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
CA2488566A1 (en) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CA2494811A1 (en) * 2002-08-15 2004-02-26 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
AU2003303040B2 (en) 2002-12-13 2009-04-23 Warner-Lambert Company Llc Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
NZ567457A (en) 2002-12-13 2009-08-28 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
JP2007505097A (ja) 2003-09-12 2007-03-08 ファイザー・インク アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
KR20090092307A (ko) 2006-12-22 2009-08-31 레코르다티 아일랜드 리미티드 하요도 장애에 대한 α2δ 리간드 및 ＮＳＡＩＤｓ의 복합 치료
ES2433890T3 (es) 2007-09-28 2013-12-12 Daiichi Sankyo Company, Limited Derivado de aminoácido bicíclico
CA2756750C (en) 2009-03-26 2014-05-13 Daiichi Sankyo Company, Limited A method for producing bicyclic .gamma.-amino acid derivative
JP5922118B2 (ja) 2011-06-08 2016-05-24 第一三共株式会社 イミニウム塩を経由する二環性化合物の製造方法
CN103562170B (zh) 2011-06-08 2015-09-02 第一三共株式会社 经由克莱森重排制备双环化合物的方法
BR112014014432B1 (pt) 2011-12-15 2022-03-29 Daiichi Sankyo Company, Limited Método para produzir um composto
BR112014025158B1 (pt) 2012-04-10 2021-09-21 Daiichi Sankyo Company, Limited Método para produzir um composto
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
TR200001170T2 (tr) 1997-10-27 2000-10-23 Warner-Lambert Company Farmasötik maddeler olarak faydalı siklo amino asitler ve bunların türevleri

Also Published As

Publication number Publication date
IL164060A0 (en) 2005-12-18
CA2386297A1 (en) 2001-04-26
ATE358116T1 (de) 2007-04-15
KR100593349B1 (ko) 2006-06-26
KR100566462B1 (ko) 2006-03-31
TR200201094T2 (tr) 2002-09-23
HUP0203325A2 (hu) 2003-02-28
TR200500221T2 (tr) 2005-03-21
HUP0203325A3 (en) 2003-12-29
AU778871B2 (en) 2004-12-23
DOP2000000083A (es) 2002-03-30
ATE293590T1 (de) 2005-05-15
AP2004003186A0 (en) 2004-12-31
YU29302A (sh) 2005-06-10
MY127678A (en) 2006-12-29
CR6620A (es) 2004-02-02
HK1049826B (zh) 2005-02-25
HRP20020428B1 (en) 2006-02-28
HK1049826A1 (en) 2003-05-30
CO5280060A1 (es) 2003-05-30
ES2237464T3 (es) 2005-08-01
EA005206B1 (ru) 2004-12-30
CA2386297C (en) 2010-02-09
MA26842A1 (fr) 2004-12-20
DE60019628T2 (de) 2006-01-19
ZA200202543B (en) 2003-09-23
JP2005036009A (ja) 2005-02-10
NO20021780D0 (no) 2002-04-16
PE20010740A1 (es) 2001-07-27
PA8505201A1 (es) 2002-08-29
IS7497A (is) 2004-10-08
AP2002002517A0 (en) 2002-06-30
EP1226110A1 (en) 2002-07-31
CU23112A3 (es) 2006-02-27
BG106719A (bg) 2003-02-28
NO20043663L (no) 2002-04-16
YU73004A (sh) 2005-11-28
AR045456A2 (es) 2005-10-26
CZ295960B6 (cs) 2005-12-14
TW200505824A (en) 2005-02-16
BR0014972B1 (pt) 2011-09-06
HRP20020428A2 (en) 2005-02-28
SV2001000188A (es) 2001-09-07
SK5232002A3 (en) 2003-07-01
US6689906B1 (en) 2004-02-10
HRP20040709A2 (en) 2004-12-31
AR026087A1 (es) 2002-12-26
IS6348A (is) 2002-04-17
ECSP045393A (es) 2004-10-23
TWI225855B (en) 2005-01-01
BR0014972A (pt) 2002-07-16
US6835751B2 (en) 2004-12-28
ES2282785T3 (es) 2007-10-16
IL149143A (en) 2007-02-11
CN1382118A (zh) 2002-11-27
NZ517961A (en) 2002-12-20
JP2003512348A (ja) 2003-04-02
PT1226110E (pt) 2005-07-29
AU1092001A (en) 2001-04-30
DZ3197A1 (fr) 2001-04-26
IL149143A0 (en) 2002-11-10
AU2005201268A1 (en) 2005-04-21
CZ20021310A3 (cs) 2003-05-14
WO2001028978A1 (en) 2001-04-26
NO20021780L (no) 2002-04-16
EA200200293A1 (ru) 2002-10-31
MXPA02003229A (es) 2002-09-30
JP3744928B2 (ja) 2006-02-15
HN2000000224A (es) 2001-04-11
KR20020040900A (ko) 2002-05-30
DE60019628D1 (de) 2005-05-25
EP1506955B1 (en) 2007-03-28
US20040152779A1 (en) 2004-08-05
EP1226110B1 (en) 2005-04-20
EP1506955A1 (en) 2005-02-16
GT200000183AA (es) 2005-06-17
DE60034157D1 (de) 2007-05-10
KR20060013701A (ko) 2006-02-13
PL354607A1 (en) 2004-01-26
EE200200211A (et) 2003-06-16
SI1226110T1 (en) 2005-08-31
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
UA72931C2 (uk) 2005-05-16
DE60034157T2 (de) 2007-12-13
JP3632191B2 (ja) 2005-03-23
OA12070A (en) 2003-11-10
BG108860A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
CN1165518C (zh) 作为药学试剂的双环氨基酸类化合物
CN1310872C (zh) 单和双取代的3－丙基－γ－氨基丁酸
CN1303059C (zh) 作为药物的环状氨基酸及其衍生物
CN1186332C (zh) 新的甲状腺受体配位体及方法ⅱ
CN1033086C (zh) 苯基烷酸衍生物的制造方法
CN1495160A (zh) 1-取代-1-氨基甲基-环烷衍生物（＝加巴喷丁类似物）、其制备及其在治疗神经病方面的用途
CN1016778B (zh) 螺-取代的戊二酸单酰胺
CN1170811C (zh) 支链氨基酸依赖性氨基转移酶的抑制剂及其在治疗糖尿病性视网膜病中的应用
CN1720219A (zh) 稠合二环或三环氨基酸
CN1711081A (zh) 对钙通道α－2－δ亚基具有亲合力的脯氨酸衍生物
CN1100032C (zh) 3,4－二取代的苯基乙醇氨基1,2,3,4,－四氢化萘甲酰胺衍生物
CN1200729A (zh) 用作止痛剂的旋光苯基嘧啶衍生物
CN1610544A (zh) 用于预防和治疗内脏疼痛和胃肠疾病的方法
CN1856301A (zh) 治疗性β－氨基酸
CN1202103A (zh) 兴奋性的氨基酸受体拮抗剂
CN1345317A (zh) (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物
CN1047857A (zh) α-羟基-3-苯氧基丙胺衍生物及其制造
CN1177842C (zh) 新的沉香呋喃衍生物、它们的药物组合物及它们制备药物的用途
CN1038283A (zh) 氨基酸酯、它们的制备方法、含有它们的药物及其应用
CN1046935C (zh) 苯基烷酸衍生物,其制备方法及其光学异构体分离方法
HK1061841B (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
HK1030768B (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
CN1050386A (zh) 吲哚并苯并喹啉衍生物，它们的制备和它们用作抗心律失常药
HK1083095A (en) Fused bicyclic or tricyclic amino acids
HK1072004A (en) Method for preventing and treating visceral pain and gastrointestinal disorders

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee